Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.

Published on Jan 1, 2020in Histopathology3.626
· DOI :10.1111/HIS.13946
Michelle R Downes6
Estimated H-index: 6
(U of T: University of Toronto),
Elzbieta Slodkowska15
Estimated H-index: 15
(U of T: University of Toronto)
+ 2 AuthorsBin Xu25
Estimated H-index: 25
(MSK: Memorial Sloan Kettering Cancer Center)
Sources
Abstract
AIMS: Programmed death-ligand 1 (PD-L1) expression by tumour cells (TC) is a mechanism for tumour immune escape through down-regulation of antitumour T cell responses and is a target for immunotherapy. PD-L1 status as a predictor of treatment response has led to the development of multiple biomarkers with different reference cut-offs. We assessed pathologist consistency in evaluating PD-L1 immunopositivity by examining the inter- and intraobserver agreement using various antibody clones and different cancer types. METHODS AND RESULTS: PD-L1 expression in TC and immune cells (IC) was manually scored in 27 head and neck squamous cell carcinoma (HSCC), 30 urothelial carcinoma (UC) and breast carcinoma (BC) using three commercial clones (SP263, SP142, 22C3) and one platform-independent test (E1L3N). For interobserver agreement, PD-L1 status was evaluated blindly by three pathologists. For intraobserver agreement, PD-L1 expression was re-evaluated following a wash-out period. Intraclass correlation coefficient (ICC), overall percentage agreement (OPA) and κ-values were calculated. Using clinical algorithms, the percentage of PD-L1-positive cases in HSCC, BC and UC were 15-81%, 47-67% and 7-43%, respectively. The percentage of PD-L1 positive cases relied heavily on the algorithm/cut-off values used. Almost perfect interobserver agreement was achieved using SP263 and E1L3N in HSCC, 22C3, SP142 and E1L3N in BC and 22C3 in UC. The SP142 clone in UC and HSCC showed moderate agreement and was associated with lower ICC and decreased intraobserver concordance. CONCLUSIONS: Excellent inter- and intraobserver agreement can be achieved using SP263, 22C3 and E1L3N, whereas PD-L1 scoring using SP142 clone is associated with a higher level of subjectivity.
📖 Papers frequently viewed together
14 Authors (Ulrich Sommer, ..., Arndt Hartmann)
2 Citations
10 Authors (Luqiao Luo, ..., Zhi Li)
6 Citations
References37
Newest
#1Sylvia Adams (NYU: New York University)H-Index: 50
#2Peter Schmid (QMUL: Queen Mary University of London)H-Index: 73
Last. Javier CortesH-Index: 76
view all 21 authors...
ABSTRACT Background Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. Patients and methods Eligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Pati...
244 CitationsSource
#1Sylvia Adams (NYU: New York University)H-Index: 50
#2Jennifer R. Diamond (Anschutz Medical Campus)H-Index: 22
Last. John D. PowderlyH-Index: 37
view all 12 authors...
Importance The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple-negative breast cancers. To extend the observed activity, combinatorial approaches are being tested with standard cytotoxic chemotherapies known to induce immunogenic tumor cell death. Objective To examine the safety, tolerability, and preliminary clinical activity of atezolizumab plus nab-paclitaxel in metastatic triple-n...
115 CitationsSource
#1Quirine F. Manson (UU: Utrecht University)H-Index: 8
#2Willemijne A. M. E. Schrijver (UU: Utrecht University)H-Index: 10
Last. Paul J. van Diest (UU: Utrecht University)H-Index: 66
view all 5 authors...
Programmed death-1 (PD-1) is an immune checkpoint that is able to inhibit the immune system by binding to its ligand programmed death-ligand 1 (PD-L1). In many cancer types, among which breast cancer, prognostic and/or predictive values have been suggested for both PD-1 and PD-L1. Previous research has demonstrated discrepancies in PD-L1 expression between primary breast tumors and distant metastases, however data so far have been scarce. We therefore evaluated immunohistochemical expression lev...
28 CitationsSource
#1Ezra E.W. Cohen (UCSD: University of California, San Diego)H-Index: 78
#2Denis Soulières (UdeM: Université de Montréal)H-Index: 43
Last. Dan P. ZandbergH-Index: 10
view all 104 authors...
Summary Background There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. We aimed to compare the efficacy and safety of pembrolizumab versus standard-of-care therapy for the treatment of head-and-neck squamous cell carcinoma. Methods We did a randomised, open-label, phase 3 study at 97 medical centres in 20 countries. Patients with head-and-...
521 CitationsSource
#1Elisabeth Specht Stovgaard (UCPH: University of Copenhagen)H-Index: 7
#2Anne Dyhl-Polk (UCPH: University of Copenhagen)H-Index: 3
Last. Dorte Nielsen (UCPH: University of Copenhagen)H-Index: 38
view all 5 authors...
Purpose To systematically review the literature on the expression of PD-L1 in primary BC, variation of expression between subtypes and effect on overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS). Additionally, for studies in the neoadjuvant setting, we have reviewed the ability of PD-L1 to predict pathological complete response (pCR).
21 CitationsSource
#1Hitomi Sakai (Kindai University)H-Index: 4
#2Masayuki Takeda (Kindai University)H-Index: 30
Last. Kazuhiko Nakagawa (Kindai University)H-Index: 97
view all 9 authors...
Abstract Objectives Immune-checkpoint inhibitors (ICIs) are now an established therapeutic option for advanced non–small cell lung cancer (NSCLC). It has remained unclear, however, whether cytotoxic chemotherapy affects the immune microenvironment in NSCLC wild type for EGFR and ALK. Materials and methods We retrospectively evaluated changes in programmed cell death 1–ligand 1 (PD-L1) expression, tumor mutation burden (TMB), and CD8+ tumor-infiltrating lymphocyte (TIL) density in NSCLC patients ...
23 CitationsSource
#1A.D. Colevas (Stanford University)H-Index: 1
#2Ratislav Bahleda (Institut Gustave Roussy)H-Index: 17
Last. John D. PowderlyH-Index: 37
view all 13 authors...
ABSTRACT Background Head and neck cancer (HNC) has a poor prognosis at advanced stages. Given the immunosuppressive tumor microenvironment in HNC, inhibition of the programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) signaling pathway represents a promising therapeutic approach. Atezolizumab (anti-PD-L1) is efficacious against many tumor types. Here we report the clinical safety and activity from the HNC cohort of the phase Ia PCD4989g clinical trial. Patients and methods Patients with pre...
50 CitationsSource
#1Enrico MunariH-Index: 27
#2Giulio Rossi (AUSL: Academy for Urban School Leadership)H-Index: 61
Last. Giuseppe BoginaH-Index: 22
view all 20 authors...
Pembrolizumab is the only programmed cell death 1/programmed death-ligand 1 inhibitor for treatment of patients with non–small cell lung cancer, with a companion diagnostic assay, the 22C3 PharmDx. Although in many studies 22C3 and Ventana’s SP263 appear to yield overlapping results, they show discr
48 CitationsSource
Abstract Objectives The Blueprint (BP) Programmed Death Ligand 1 (PD-L1) Immunohistochemistry Comparability Project is a pivotal academic/professional society and industrial collaboration to assess the feasibility of harmonizing the clinical use of five independently developed commercial PD-L1 immunohistochemistry assays. The goal of BP phase 2 (BP2) was to validate the results obtained in BP phase 1 by using real-world clinical lung cancer samples. Methods BP2 were conducted using 81 lung cance...
341 CitationsSource
#1Chiyun Wang (U of T: University of Toronto)H-Index: 1
#2Elan Hahn (U of T: University of Toronto)H-Index: 1
Last. Bin Xu (U of T: University of Toronto)H-Index: 25
view all 10 authors...
Summary Programmed death-ligand 1 (PD-L1) expression by tumor cells is a mechanism for down-regulation of antitumor T-cell responses and is a target for immunotherapy in various cancers. PD-L1 status as a predictor of treatment response has led to the development of multiple platforms with different reference cutoffs. We studied 128 cases of genitourinary and head/neck carcinomas, aiming to assess the frequency of PD-L1 positivity, interobserver reliability of PD-L1 interpretation, and the conco...
22 CitationsSource
Cited By21
Newest
#1Katia R. M. Leite (USP: University of São Paulo)H-Index: 31
#2Carlos BarriosH-Index: 28
Last. Fernando Augusto SoaresH-Index: 60
view all 6 authors...
Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. New targeted therapies such as anti-PD-L1 agents are emerging as an option to treat advanced TNBC. A panel of 6 national experts with an active interest in breast cancer convened online. Panel members had either clinical or pathology experience in breast cancer. The expert...
Source
#1Mieke R Van Bockstal (Cliniques Universitaires Saint-Luc)H-Index: 1
view all 32 authors...
Patients with advanced triple-negative breast cancer (TNBC) benefit from treatment with atezolizumab, provided that the tumor contains ≥1% of PD-L1/SP142-positive immune cells. Numbers of tumor-infiltrating lymphocytes (TILs) vary strongly according to the anatomic localization of TNBC metastases. We investigated inter-pathologist agreement in the assessment of PD-L1/SP142 immunohistochemistry and TILs. Ten pathologists evaluated PD-L1/SP142 expression in a proficiency test comprising 28 primary...
Source
#1Gaetano PaolinoH-Index: 3
#2Liron Pantanowitz (UM: University of Michigan)H-Index: 57
Last. Pasquale Pisapia (University of Naples Federico II)H-Index: 17
view all 14 authors...
Immunohistochemical assessment with combined positive score (CPS) of programmed death-ligand 1 (PD-L1) is the prerequisite for administration of checkpoint inhibitor therapy in head and neck squamous cell carcinoma (HNSCC). Practicing pathologists are required to assess PD-L1 in routinary work and can be faced up with practical issues not always addressed in clinical trials or guidelines, such as choice of specimen to test, the intrinsic heterogeneity in PD-L1 expression in tumors and the potent...
Source
#1Behrus Puladi (RWTH Aachen University)H-Index: 1
#2Mark Ooms (RWTH Aachen University)H-Index: 1
Last. Till Braunschweig (RWTH Aachen University)H-Index: 20
view all 9 authors...
Immune checkpoint inhibitors (ICI) represent a new therapeutic approach in recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). The patient selection for the PD-1/PD-L1 inhibitor therapy is based on the degree of PD-L1 expression in immunohistochemistry reflected by manually determined PD-L1 scores. However, manual scoring shows variability between different investigators and is influenced by cognitive and visual traps and could therefore negatively influence treatment decisio...
Source
1 CitationsSource
#1Ilaria GirolamiH-Index: 8
#2Liron Pantanowitz (UM: University of Michigan)H-Index: 57
Last. Albino EccherH-Index: 17
view all 10 authors...
BACKGROUND Programmed death-ligand 1 (PD-L1) expression with combined positive score (CPS) ≥1 is required for administration of checkpoint inhibitor therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The 22C3 pharmDx Dako immunohistochemical assay is the one approved as companion diagnostic for pembrolizumab, but many laboratories work on other platforms and/or with other clones, and studies exploring the potential interchangeability of assays have appeared. EVIDENCE ...
1 CitationsSource
Purpose null The programmed death ligand 1 (PD-L1) SP142 assay with a 1% immune cell (IC) cutoff is approved for the selection of advanced triple-negative breast cancer (TNBC) patients for atezolizumab treatment. We aimed to evaluate the interobserver concordance of PD-L1 scoring and inter-assay variability of various PD-L1 assays in TNBC. null Methods null Thirty patients with primary TNBC were selected, and SP142, SP263, 22C3, and E1L3N assays were performed. PD-L1 staining in ICs and tumor ce...
Source
#2Wilko Weichert (TUM: Technische Universität München)H-Index: 79
Checkpoint inhibitors have revolutionized oncological treatment in many cancers and added a new immuno-oncological treatment pillar to the medicinal arsenal of conventional and molecularly targeted therapies. In monotherapy and in combination therapies, however, not all patients respond equally well, even in generally responsive tumor entities. Therefore, since the introduction of these therapies, a major focus has been the research on and implementation of predictive markers for patient selecti...
Source
#1Kyu Sang Lee (New Generation University College)H-Index: 13
#2Gheeyoung Choe (New Generation University College)H-Index: 31
Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibition has revolutionized the treatment paradigm of urothelial carcinoma (UC). Several PD-L1 assays are conducted to formulate appropriate treatment decisions for PD-1/PD-L1 target therapy in UC. However, each assay has its own specific requirement of antibody clones, staining platforms, scoring algorithms, and cutoffs for the determination of PD-L1 status. These prove to be challenging constraints to pathology laboratori...
Source
#1Nishant Thakur (Catholic University of Korea)H-Index: 12
#2Kwang Yeol Paik (Catholic University of Korea)H-Index: 1
Last. Yosep Chong (Catholic University of Korea)H-Index: 11
view all 4 authors...
Periampullary cancers (PACs) are characterized by tumor-infiltrating lymphocytes (TILs), severe fibrosis, and epithelial to mesenchymal transition (EMT). The immune checkpoint marker programmed death-1 (PD-1) and its ligands 1 and 2 have gained popularity in cancers with TILs. Evidence suggests a strong relationship between immune checkpoint markers and EMT in cancers. Here, we evaluated the expression and prognostic significance of immune checkpoint and EMT markers in PAC using an automated ima...
Source